Ishibashi Mariko, Morita Rimpei, Tamura Hideto
Department of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8602, Japan.
Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan.
Cancers (Basel). 2021 Jan 13;13(2):279. doi: 10.3390/cancers13020279.
The signaling lymphocytic activation molecule (SLAM) family receptors are expressed on various immune cells and malignant plasma cells in multiple myeloma (MM) patients. In immune cells, most SLAM family molecules bind to themselves to transmit co-stimulatory signals through the recruiting adaptor proteins SLAM-associated protein (SAP) or Ewing's sarcoma-associated transcript 2 (EAT-2), which target immunoreceptor tyrosine-based switch motifs in the cytoplasmic regions of the receptors. Notably, SLAMF2, SLAMF3, SLAMF6, and SLAMF7 are strongly and constitutively expressed on MM cells that do not express the adaptor proteins SAP and EAT-2. This review summarizes recent studies on the expression and biological functions of SLAM family receptors during the malignant progression of MM and the resulting preclinical and clinical research involving four SLAM family receptors. A better understanding of the relationship between SLAM family receptors and MM disease progression may lead to the development of novel immunotherapies for relapse prevention.
信号淋巴细胞激活分子(SLAM)家族受体在多发性骨髓瘤(MM)患者的多种免疫细胞和恶性浆细胞上表达。在免疫细胞中,大多数SLAM家族分子通过招募衔接蛋白信号淋巴细胞激活分子相关蛋白(SAP)或尤文肉瘤相关转录本2(EAT-2)与自身结合,以传递共刺激信号,这些衔接蛋白靶向受体胞质区域中基于免疫受体酪氨酸的开关基序。值得注意的是,SLAMF2、SLAMF3、SLAMF6和SLAMF7在不表达衔接蛋白SAP和EAT-2的MM细胞上强烈且组成性表达。本综述总结了关于SLAM家族受体在MM恶性进展过程中的表达和生物学功能的最新研究,以及由此产生的涉及四种SLAM家族受体的临床前和临床研究。更好地理解SLAM家族受体与MM疾病进展之间的关系可能会导致开发用于预防复发的新型免疫疗法。